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Quality activities associated with hospital 
tissue services
C.M. Hillberry and A.J. Schlueter
Quality assurance is a vital component of a tissue service that aims 
to meet regulatory requirements and provide safe and functional 
tissue for surgical procedures in the institution. Many hospital 
transfusion services have or are in the process of assuming tis-
sue service functions for their institutions, and the concepts of 
tissue quality assurance requirements should be familiar to the 
transfusion service. This review discusses the key aspects of tissue 
service quality assurance, including requirements for FDA regis-
tration, selection and qualification of tissue suppliers, recordkeep-
ing, management of occurrences and tissue recalls, adverse event 
reporting, audits, and quality control. Comparing the similarities 
and differences between tissue and blood component regulatory 
requirements suggests transfusion service processes can be read-
ily adapted to incorporate quality assurance for tissue service ac-
tivities. 
Immunohematology 2009;25:102–106.
Key Words: tissue service, quality assurance, records, re-
calls, adverse event reporting, supplier qualification
With the implementation of the US Food and Drug Administration (FDA) current Good Tissue Prac-tices (cGTP) tissue regulations on May 25, 2005, 
and the introduction of the Joint Commission accrediting 
standards on July 1, 2005, many transfusion services are 
overseeing their hospital’s tissue service functions.1,2 Ad-
ditional accrediting agencies (e.g., AABB and College of 
American Pathologists) may also be inspecting tissue ser-
vice activities as part of their overall laboratory inspection. 
Thus, quality assurance personnel in transfusion services, 
who are very experienced in activities related to qualifying 
suppliers, product tracking, recalls, and event reporting, 
are assuming similar tissue service responsibilities. Trans-
fusion services can incorporate many of the tissue activities 
into their current procedures; however, some procedures 
may need to be created or modified. From registration to 
adverse event reporting, this review discusses aspects of 
quality assurance needed for a tissue service, with a focus 
on allograft tissue requirements, for comparison with simi-
lar functions required for a transfusion service.
FDA HCT/P Registration
Who must register?
 Similar to the requirement for blood components, the 
FDA requires all manufacturers of products containing or 
consisting of human cells or tissues (HCT/Ps) intended for 
implantation, transplantation, infusion, or transfer into a 
human recipient to register.3 Manufacturing is defined as 
any step in the recovery, processing, storage, labeling, or 
distribution of any human cell or tissue, and the screening 
or testing of the cell or tissue donor.1 Hospital transfusion 
services that also provide tissue services commonly store 
purchased allograft bone, ligament, skin, heart valve, and 
cornea for use within their facilities.
 Hospital tissue services are exempt from the FDA 
HCT/P (tissue) registration requirements if they only per-
form the following tissue activities:
Autologous bone (or other autologous tissue) is re-• 
moved during a surgical procedure and then stored un-
til implantation into the patient at a future date within 
the same facility.3
Autologous tissue is removed and stored at another • 
establishment until future implantation at the facility 
that harvested the tissue.4
Allograft tissue is received from a supplier and stored • 
by the tissue service for use in surgical procedures only 
at that facility.3
 If the tissue service serves as a distributor to another 
facility or to another physical location under the same man-
agement, tissue registration is required.3 For example, if an 
autologous bone removed during a surgical procedure at 
one facility is transferred to another facility for implanta-
tion, or if purchased allograft tissue is shipped directly to 
another hospital, the shipping tissue service must register 
with the FDA
What is the registration process?
 If the tissue service performs a manufacturing step that 
is not one of the exempt activities, it must register with the 
FDA by using Form FDA 3356. The registration form can be 
obtained by writing to the Center for Biologics Evaluation 
and Research (CBER) or downloading the form at www.fda.
gov/opacom/morechoices/fdaforms/cber.html.5 The tissue 
service, like the transfusion service, is required to provide 
facility contact information, types of tissues manufactured, 
manufacturing steps performed at the facility, and the 
contact information of the reporting official. Even though 
tissues may be handled or manufactured by various units 
within the hospital, one tissue registration may be submit-
ted that includes all tissue activities performed at the fa-
cility. For example, allograft surgical tissue, hematopoietic 
stem cells, and reproductive tissue may be managed inde-
pendently in the hospital, but all could be reported to the 
FDA in a single tissue registration. The tissue registration 
must be updated annually, in December, or within 5 days of 
initiating any new manufacturing function.3
Review
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Qualification and Selection of Tissue Suppliers
 Hospital transfusion services have policies and proce-
dures for selecting and qualifying blood component and re-
agent suppliers that can be expanded to encompass tissue 
suppliers. A common difficulty encountered when quali-
fying tissue suppliers is that many of the companies sell-
ing tissue products are not the manufacturer but simply a 
distributor of the product. This makes it difficult to deter-
mine whom to qualify as the supplier, especially with the 
frequent buyouts and mergers that occur in the tissue in-
dustry. In some cases the distributor can be qualified inde-
pendently, but in other instances the distributor will refer 
the tissue service to the parent manufacturing company for 
much of the information necessary to complete the qualifi-
cation. When qualifying a supplier (either a distributor or 
manufacturer), predetermined selection criteria must be 
defined. Selection criteria are used to evaluate the quality 
of the products produced by the manufacturer by review-
ing items described in Table 1. Additional secondary selec-
tion criteria may also be considered as described in Table 
2. The secondary selection criteria assess factors that may 
facilitate administrative interactions with the supplier and 
can be useful in distinguishing among several companies 
that provide products of similar quality.
 Many companies have information on their Web sites, 
including state licenses, product information, package in-
serts, and accreditation certificates. A public query function 
on the FDA Web sites (www.fda.gov/cber/tissue/tissreg-
data.htm) allows anyone to search for a company’s tissue 
registration information. Product recalls can also be found 
on the FDA Web site at www.fda.gov/opacom/Enforce.
html. It may be useful to contact the manufacturer’s quality 
assurance department through a phone call or by sending a 
supplier questionnaire to obtain any additional information 
needed to complete the qualification. In rare instances, the 
tissue service’s medical director may request an on-site au-
dit of the manufacturer, after review of the Form FDA 483s 
received by the manufacturer or after a recall of any of its 
products. However, some tissue manufacturers may not al-
low customers to observe some of their practices, to protect 
proprietary processes.
 Periodically after the initial selection and qualification, 
the tissue supplier’s performance should be reevaluated. 
Reevaluation may include items from the initial qualification 
as well as clinical feedback from the surgeons (e.g., ease of 
tissue use, clinical effectiveness of the tissue) and supplier 
performance issues (e.g., timely product delivery, product 
back orders).
Tissue Tracking Records
 A key task in tissue management is accurate tracking 
of tissue movement in and out of the inventory. The tissue 
service must be able to track the tissue from the time of 
receipt into the facility until the final disposition (implan-
tation, return to the supplier, or disposal), analogous to the 
requirement for blood component tracking for transfusion 
services.1 Tissue tracking should also include documentation 
of all instances in which the tissue was sent to patient care 
areas under established storage conditions and returned to 
inventory after meeting acceptance criteria. Tissue storage 
and transport conditions are based on the manufacturer’s 
storage and handling instructions and the storage time 
determined for the validated transport containers. This 
information must be communicated to the surgical areas 
and ideally incorporated into the nursing policies for tis-
sue handling. The tissue service also establishes criteria 
for accepting returned unused tissues into inventory. The 
acceptance criteria may include the length of time in the 
validated transport container, inspection of package seals, 
tissue container integrity, and product temperature (e.g., 
product remains frozen).
 The ability to track all tissue is essential in the event of a 
product recall that may require patient notification. Tissue 
tracking may use electronic or paper records, but any track-
ing method must contain several key pieces of information. 
These include the unique identifier (donor identification 
number, lot number), final disposition, tissue supplier, and 
the patient name and identifier if the tissue was implanted. 
The tissue service may receive several pieces of tissue with 
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Table 1. Qualification criteria
Types of tissues manufactured
FDA Form 483 citations and corrective actions
Manufacturing processes6 (including current FDA registration for the 
manufacturing steps performed)
Qualifications of contract companies performing manufacturing steps 
(e.g., tissue recovery, laboratory testing)
Written quality program
Nature of product recalls
Clinical Laboratory Improvement Amendments (CLIA) certification
Licensed by the state if applicable (CA, FL, MD, NY)
Table 2. Additional selection criteria for tissue suppliers
Nature of tissue tracking system
Product cost and expiration dates
Customer service (product return policy, availability of product)
Method for monitoring contracted companies6
Method of tissue recall notification
Accreditation by American Association of Tissue Banks (AATB) or Eye 
Bank Association of America (EBAA)
Method for adverse event reporting
Allowance for customer audits
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the same donor identifier and lot number from the same 
supplier. Each of these tissues must be tracked individu-
ally. If the tissue service decides to assign new identification 
numbers, the original identification number must remain 
part of the tracking record. Alternatively, a subunit number 
may be added to the original identification number so that 
the original number remains part of the final tissue identifi-
cation.
 Commercial tissue tracking software is available to 
assist the tissue service in tracking tissue inventory from 
tissue receipt to final disposition. Some programs have the 
capability of data entry through the use of bar code scan-
ning. The data can be quickly retrieved from such programs 
in the event of product recall or adverse event.
 For tracking, recall, and billing purposes, the definition 
of an implanted tissue and a wasted tissue must be clear for 
both the surgical team and the tissue service. A conserva-
tive approach is to track any tissue that has been exposed to 
the patient (e.g., package opened in the surgical suite, tissue 
placed on the patient and removed) similar to an implanted 
tissue because the patient may have been exposed to po-
tential infectious agents from such tissue either by direct 
contact with the tissue or indirectly from surgical staff or 
instruments touching the tissue and then the patient during 
the surgical procedure. If this conservative approach is used 
for tracking purposes, the tissue service must still distin-
guish which tissues remained in the patient at the end of the 
case, as patients can only be billed for these tissues. Tissues 
to which the patient was simply exposed during the surgical 
procedure would be considered wasted for billing purposes. 
Thus, it is essential that the patient care staff communicate 
clearly to the tissue service whether the implanted tissue 
was left in the patient or the patient was only exposed to the 
tissue.
 A key element in tracking tissues that is different from 
tracking blood component disposition is supplier notifica-
tion of final tissue disposition. Many suppliers request that 
tissue services provide final tissue disposition information 
to them so that proper recall notification may occur if it 
becomes necessary.2 Some manufacturers use carbon copy 
notification forms, which facilitates retention of a copy of 
the completed form for tissue service records; however, cur-
rently there is no standard method or format for providing 
final tissue disposition information to the manufacturer. A 
variety of information may be requested such as patient de-
mographics, surgeon name, date of final disposition, type of 
final disposition (e.g., implanted, wasted), facility contact 
information, and tissue identifier. Health Insurance Porta-
bility and Accountability Act (HIPAA) regulations allow the 
release of protected health information (PHI) to the tissue 
manufacturers without explicit patient consent for the pur-
pose of routine product tracking and ultimately to enable 
product recalls, including locating and notifying individuals 
who have received recalled tissues.2 However, there is no 
requirement that the tissue service must release PHI when 
providing routine final tissue disposition information. If the 
tissue service chooses not to release PHI, in the event of a 
tissue recall it assumes responsibility for determining who 
received the recalled tissue, as the manufacturer would be 
unable to provide patient information with the recall no-
tice.
 The record retention time for tissue records is longer 
than the retention time for blood component records. The 
Joint Commission Accreditation Program standards re-
quire that several tissue records must be maintained for a 
minimum of 10 years or longer (if required by state or fed-
eral laws) beyond the date of distribution, transplantation, 
disposition, or expiration, whichever is latest.2 These tissue 
records include the tissue supplier, the original numeric or 
alphanumeric donor and lot identification, name(s) of the 
recipient(s) or the final disposition of each tissue, and the 
expiration dates of all tissues. Other records that are re-
quired to be retained for a minimum of 10 years are tissue 
storage temperatures, outdated procedures, manuals, and 
publications.2
Management of Tissue Recalls
 Tissue recalls are unlike blood recalls in that they often 
involve numerous tissues, and the tissues may have been 
handled by multiple companies at various steps between 
tissue procurement and distribution. Thus, for example, 
a tissue recalled by a parent company may have been dis-
tributed and labeled by a subsidiary, making the identity 
of the recalled item obscure. In the event of a tissue recall, 
the tissue manufacturer generally sends the recall notifi-
cation to the entity that ordered the tissue (e.g., the hospi-
tal procurement service, the operating room, or the tissue 
service). The FDA also lists recalls at www.fda.gov/safety/
recalls/default.htm and www.recalls.gov/. In addition, 
there are companies that compile recall notifications from 
multiple sources and distribute them to their subscribers. 
Subscribing to such a service may be useful to help ensure 
that the tissue service is aware of all pertinent recalls. The 
recall notification includes the reason for the recall, the 
description of the recalled tissue (catalog number, product 
name), and the tissue identification number and may also 
include how to handle any recalled tissue that may still 
be in inventory. Recalls are almost always voluntary on 
the part of the manufacturer, either because it discovered 
a problem or because the FDA raised concerns about the 
product. Only rarely does the FDA mandate a recall.
 Regardless of whether the recall is voluntary or man-
dated, the same process should be followed by the tissue 
service. After receiving the recall notice, the tissue service 
should immediately check the current inventory for the re-
called tissue and quarantine the tissue to prevent dispens-
ing it for a patient. The quarantined tissue should then be 
discarded or returned to the manufacturer as instructed in 
the recall notification. After reviewing the available inven-
tory, the tissue service should determine whether any of 
the recalled tissue was previously implanted.
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 The tissue service should have a recall policy that out-
lines how to handle the recall information and potential 
notification of the patients who have been affected. After 
reviewing the reason for the tissue recall, the tissue service 
medical director is responsible for determining when to 
notify the implanting surgeon. The medical director may 
determine that notification is not necessary in some cir-
cumstances, for example, if the patient is deceased or a 
minor error in labeling occurred that does not affect the 
tissue identity or integrity. Surgeon notification should 
include the reason for the recall, the patient information, 
recommendation regarding patient notification, and a 
request for information related to any medical complica-
tions from the implanted tissue. Patient notification may 
be deemed necessary by the tissue service medical direc-
tor in the event that the patient’s health is at risk from the 
implanted tissue (e.g., positive microbial tested product, 
tissue donor tested positive for a communicable disease 
agent). If patient notification is deemed necessary and the 
surgeon does not want to notify the patient or no longer is 
on staff at the institution, the tissue service medical 
director should take the responsibility for notifying the pa-
tients. Notifications can occur through phone calls, hand-
delivered letters to individuals at clinic appointments, or 
registered letters, depending on the specific situation. If 
the letters are sent to the patient through registered mail, 
the tissue service should be aware that a patient’s family 
member may sign for the letter and the patient may not be 
notified.7
Adverse Event Reporting
 The FDA defines adverse reaction to tissue as a noxious 
and unintended response to any HCT/P for which there is a 
reasonable possibility that the HCT/P caused the response. 
Every hospital needs a process for identifying and report-
ing adverse events. Because adverse events may be acute or 
delayed in presentation the adverse event reporting process 
may involve several departments throughout the hospital.8 
It is helpful to educate surgeons, the hospital epidemiology 
department, or even the patient’s primary care provider to 
encourage identification of potential tissue-related adverse 
events. Communication of the adverse event to the tissue 
service begins the investigation and reporting process.
 One or more designated services within the hospital 
(e.g., hospital epidemiology, hospital quality assurance, tis-
sue service) must be responsible for accumulating reports 
and investigating all tissue adverse events. In some hospitals, 
the tissue service is notified of any tissue-related adverse event 
and performs the investigation with consultation with other 
departments as needed. The tissue service medical director 
would then be responsible for review of the data related to 
the adverse event and determination of the likelihood that 
the tissue may be implicated. If tissue involvement cannot 
reasonably be excluded, the manufacturer should be noti-
fied.2 In turn, all manufacturers must report adverse events 
to the FDA if they are fatal, are life-threatening, result in 
permanent impairment of function or permanent damage to 
body structure, or necessitate medical or surgical interven-
tion.1 Unlike tissue adverse event reporting, blood donor 
or recipient adverse event reporting only involves 
fatality reports. Adverse events may be related to either 
disease transmission or failure of intended tissue function. 
Examples of adverse reactions include bacterial or fungal 
surgical site infections, virus or cancer transmission, or 
increased intensity of medical care owing to the tissue 
implanted.
 The manufacturer’s quality assurance department may 
request additional information from the tissue service in-
cluding patient laboratory tests, patient medical history, 
and current patient status to assist them in their internal 
investigation. Again, all of this may be provided without 
violation of HIPAA regulations. It is ultimately the manu-
facturer’s responsibility to report the adverse event to the 
FDA; however, the FDA encourages health-care profes-
sionals to voluntarily report any adverse reactions related 
to a communicable disease through MedWatch using Form 
3500 in addition to notification of the tissue manufacturer. 
If the tissue service is the tissue manufacturer (e.g., the har-
vesting facility for autologous tissue that has been shipped 
to another institution for implantation), the tissue service 
must submit a report within 15 days through MedWatch us-
ing FDA Form 3500A.9 The reporting process for adverse 
events related to blood components differs from the one for 
tissue in that the reports for transfusion-related fatalities 
are not submitted on a standardized form.
 If the adverse event is related to the failure of a tissue 
to function as expected, the tissue service should begin its 
investigation by reviewing internal handling of the tissue. 
The investigation may include review of records related to 
the tissue integrity at set time points, including each time 
the product was issued and received into the inventory, as 
well as storage equipment temperature records. In addition 
to conducting an internal investigation, the tissue service 
should notify the manufacturer of the problem through the 
sales representative, a customer service line, or a manufac-
turer complaint form located on the manufacturer’s Web 
site.
 It is essential that all adverse reactions be investigated 
and reported to the appropriate individuals. This information 
will allow the manufacturer to track recurring complaints 
about tissue problems and perform its own internal inves-
tigations. The FDA uses the information reported through 
MedWatch to determine whether a reaction is an isolated 
event or an emerging problem. Currently the United Net-
work of Organ Sharing (UNOS) under a contract with the 
Centers for Disease Control and Prevention (CDC) is devel-
oping a system to allow easier reporting of adverse events 
and tracking of tissues between the tissue manufacturers 
and the hospitals. This system, called the Transplantation 
Transmission Sentinel Network (TTSN), will include five 
Quality activities of tissue services
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key elements including registration of donors and recipients, 
reporting of adverse events, relay of information to regula-
tory and public health agencies, and community education. 
An electronic mechanism for tracking and sharing informa-
tion between manufacturers and hospitals is being devel-
oped for TTSN. Pilot testing for this electronic reporting 
system occurred in the spring of 2008.10 A similar program, 
called the Hemovigilance Module, under the US Biovigi-
lance Network, will track recipient adverse events associated 
with blood component transfusions.
Other Tissue QA Functions
 The transfusion service can easily incorporate tissue 
into its current processes for auditing, occurrence manage-
ment, and other quality control activities. Records can be 
audited for documentation of tissue receipt and acceptance 
into inventory, tissue implant information in the patient’s 
medical record, final disposition of the tissue (implanted, 
returned to the supplier, or wasted), and quality control of 
tissue storage devices. Observation audits can be performed 
for tasks such as preparing tissue transport containers, re-
turning product into inventory, and notifying the tissue 
manufacturer of the tissue’s final disposition.
 Occurrences involving tissues (e.g., equipment failures, 
deviations from standard operating procedures, supplier 
issues, documentation errors or omissions) can be tracked 
through the same occurrence management system current-
ly used by the transfusion service for blood components. If 
the facility manufactures tissues, tracking may also include 
occurrences with product labeling, processing steps, and 
testing (microbial and infectious disease).
 Quality control of equipment and testing is routine to 
the transfusion service, and similar functions are needed 
for the tissue service. In particular, monitoring of tissue 
storage conditions is essential as part of the verification that 
high tissue quality is maintained. The tissue service must 
store the tissues under the appropriate storage conditions 
as defined on the tissue package label.11 (An accompanying 
review further discusses the intricacies of tissue storage.12) 
Some tissue suppliers require the tissue service to sign a 
statement that the tissues were maintained at the accept-
able storage conditions. This acknowledgment may occur 
at the time tissues are returned to the tissue supplier or 
through a supplier consignment agreement.
Conclusions
 Tissue service quality assurance functions are generally 
quite parallel to transfusion service quality assurance func-
tions.  They include tissue service registration with the FDA, 
qualification of suppliers, ensuring a robust tissue tracking 
process, management of recalls, and reporting of adverse 
events. With attention to minor differences between tissue 
and blood component requirements, tissue service quality 
assurance activities can readily be incorporated into the 
routine activities of a transfusion service quality assurance 
team.
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